Literature DB >> 10415727

Fluorogenic MMP activity assay for plasma including MMPs complexed to alpha 2-macroglobulin.

B Beekman1, J W Drijfhout, H K Ronday, J M TeKoppele.   

Abstract

Elevated MMP activities are implicated in tissue degradation in, e.g., arthritis and cancer. The present study was designed to measure MMP enzyme activity in plasma. Free active MMP is unlikely to be present in plasma: upon entering the circulation, active MMP is expected to be captured by the proteinase inhibitor alpha 2-macroglobulin (alpha 2M). Reconstituted MMP-13/alpha 2M complex was unable to degrade collagen (MW 300,000) in contrast to the low-molecular-weight fluorogenic substrate (MW < 1500). Limited access of high-MW substrates to the active site of MMPs captured by alpha 2M presents the most likely explanation. Consistently, the high-MW inhibitor TIMP (MW approximately 28,000) was unable to inhibit MMP/alpha 2M enzyme activity, whereas the low-MW inhibitor BB94 (MW approximately 500) effectively suppressed enzyme activity. By using fluorogenic substrates with Dabcyl/Fluorescein as quencher/fluorophore combin-ation, sensitive MMP-activity assays in plasma were achieved. Spiking of active MMP-13 and MMP-13/alpha 2M complex, and inhibitor studies with TIMP-1 and BB94, indicated that active MMPs are efficiently captured by alpha 2M in plasma. MMP activity was even detected in control plasma, and was significantly increased in plasma from rheumatoid arthritis patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415727     DOI: 10.1111/j.1749-6632.1999.tb07681.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  6 in total

1.  Subversion of a lysosomal pathway regulating neutrophil apoptosis by a major bacterial toxin, pyocyanin.

Authors:  Lynne R Prince; Stephen M Bianchi; Kathryn M Vaughan; Martin A Bewley; Helen M Marriott; Sarah R Walmsley; Graham W Taylor; David J Buttle; Ian Sabroe; David H Dockrell; Moira K B Whyte
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

2.  Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.

Authors:  Koert F D Kuhlmann; J W Olivier van Till; Marja A Boermeester; Philip R de Reuver; Iva D Tzvetanova; G Johan A Offerhaus; Fiebo J W Ten Kate; Olivier R C Busch; Thomas M van Gulik; Dirk J Gouma; Howard C Crawford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-05       Impact factor: 4.254

3.  Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis.

Authors:  I Tchetverikov; L R Lard; J DeGroot; N Verzijl; J M TeKoppele; F C Breedveld; T W J Huizinga; R Hanemaaijer
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

4.  Profiling the secretion of soluble mediators by end stage osteoarthritis synovial tissue explants reveals a reduced responsiveness to an inflammatory trigger.

Authors:  Lobke M Gierman; Benno van El; Frits van der Ham; Angela Koudijs; Reinout Stoop; Jan H Verheijen; Margreet Kloppenburg; Gerjo J V M van Osch; Vedrana Stojanovic-Susulic; Tom W J Huizinga; Anne-Marie Zuurmond
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

5.  Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.

Authors:  Astrid Jüngel; Caroline Ospelt; Mark Lesch; Melissa Thiel; Teresa Sunyer; Olivier Schorr; Beat A Michel; Renate E Gay; Christoph Kolling; Craig Flory; Steffen Gay; Michel Neidhart
Journal:  Ann Rheum Dis       Date:  2009-06-03       Impact factor: 19.103

6.  Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer.

Authors:  E T Waas; R M L M Lomme; J DeGroot; Th Wobbes; T Hendriks
Journal:  Br J Cancer       Date:  2002-06-17       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.